Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

June 20, 2017

Study Completion Date

June 20, 2017

Conditions
Infections, Bacterial
Interventions
DRUG

Gepotidacin

Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.

Trial Locations (3)

32809

GSK Investigational Site, Orlando

33136

GSK Investigational Site, Miami

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY